nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Mitoxantrone—lymphatic system cancer	0.139	0.207	CbGbCtD
Tolvaptan—CYP3A4—Cytarabine—lymphatic system cancer	0.121	0.18	CbGbCtD
Tolvaptan—CYP3A4—Teniposide—lymphatic system cancer	0.119	0.177	CbGbCtD
Tolvaptan—ABCB1—Vincristine—lymphatic system cancer	0.0955	0.142	CbGbCtD
Tolvaptan—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0831	0.124	CbGbCtD
Tolvaptan—ABCB1—Methotrexate—lymphatic system cancer	0.0578	0.086	CbGbCtD
Tolvaptan—CYP3A4—Vincristine—lymphatic system cancer	0.0572	0.0852	CbGbCtD
Tolvaptan—Deep vein thrombosis—Fludarabine—lymphatic system cancer	0.0101	0.0307	CcSEcCtD
Tolvaptan—Hyperuricaemia—Fludarabine—lymphatic system cancer	0.00662	0.0202	CcSEcCtD
Tolvaptan—Blood uric acid increased—Fludarabine—lymphatic system cancer	0.00625	0.019	CcSEcCtD
Tolvaptan—Respiratory failure—Fludarabine—lymphatic system cancer	0.00625	0.019	CcSEcCtD
Tolvaptan—Hyperkalaemia—Fludarabine—lymphatic system cancer	0.00603	0.0184	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.00455	0.0139	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Fludarabine—lymphatic system cancer	0.00446	0.0136	CcSEcCtD
Tolvaptan—Dehydration—Fludarabine—lymphatic system cancer	0.00414	0.0126	CcSEcCtD
Tolvaptan—Hyperuricaemia—Vincristine—lymphatic system cancer	0.00404	0.0123	CcSEcCtD
Tolvaptan—Hyperuricaemia—Mitoxantrone—lymphatic system cancer	0.00394	0.012	CcSEcCtD
Tolvaptan—Pulmonary embolism—Carmustine—lymphatic system cancer	0.00393	0.012	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Mitoxantrone—lymphatic system cancer	0.00386	0.0118	CcSEcCtD
Tolvaptan—Blood uric acid increased—Vincristine—lymphatic system cancer	0.00382	0.0116	CcSEcCtD
Tolvaptan—Respiratory failure—Vincristine—lymphatic system cancer	0.00382	0.0116	CcSEcCtD
Tolvaptan—Blood uric acid increased—Mitoxantrone—lymphatic system cancer	0.00372	0.0113	CcSEcCtD
Tolvaptan—Hyperkalaemia—Mitoxantrone—lymphatic system cancer	0.00359	0.0109	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.0035	0.0107	CcSEcCtD
Tolvaptan—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00347	0.0106	CcSEcCtD
Tolvaptan—Urine output increased—Vincristine—lymphatic system cancer	0.00339	0.0103	CcSEcCtD
Tolvaptan—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00338	0.0103	CcSEcCtD
Tolvaptan—Renal failure—Fludarabine—lymphatic system cancer	0.00338	0.0103	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00333	0.0102	CcSEcCtD
Tolvaptan—Ecchymosis—Mitoxantrone—lymphatic system cancer	0.0033	0.0101	CcSEcCtD
Tolvaptan—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00328	0.01	CcSEcCtD
Tolvaptan—Anorexia—Mechlorethamine—lymphatic system cancer	0.00322	0.00982	CcSEcCtD
Tolvaptan—Polyuria—Vincristine—lymphatic system cancer	0.0031	0.00945	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Methotrexate—lymphatic system cancer	0.00299	0.00911	CcSEcCtD
Tolvaptan—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00294	0.00895	CcSEcCtD
Tolvaptan—Hyponatraemia—Carmustine—lymphatic system cancer	0.00286	0.00872	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Carmustine—lymphatic system cancer	0.00285	0.00869	CcSEcCtD
Tolvaptan—Hyponatraemia—Vincristine—lymphatic system cancer	0.00273	0.00833	CcSEcCtD
Tolvaptan—Malnutrition—Fludarabine—lymphatic system cancer	0.00268	0.00818	CcSEcCtD
Tolvaptan—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00266	0.00811	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Mitoxantrone—lymphatic system cancer	0.00265	0.00808	CcSEcCtD
Tolvaptan—Dehydration—Vincristine—lymphatic system cancer	0.00253	0.00771	CcSEcCtD
Tolvaptan—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00249	0.00759	CcSEcCtD
Tolvaptan—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00249	0.00759	CcSEcCtD
Tolvaptan—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00248	0.00757	CcSEcCtD
Tolvaptan—Dehydration—Mitoxantrone—lymphatic system cancer	0.00247	0.00751	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00245	0.00747	CcSEcCtD
Tolvaptan—Malaise—Fludarabine—lymphatic system cancer	0.00242	0.00737	CcSEcCtD
Tolvaptan—Pruritus—Mechlorethamine—lymphatic system cancer	0.00239	0.00729	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00239	0.00727	CcSEcCtD
Tolvaptan—Anorexia—Teniposide—lymphatic system cancer	0.00238	0.00724	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00234	0.00713	CcSEcCtD
Tolvaptan—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00231	0.00705	CcSEcCtD
Tolvaptan—Discomfort—Fludarabine—lymphatic system cancer	0.00226	0.00688	CcSEcCtD
Tolvaptan—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00222	0.00677	CcSEcCtD
Tolvaptan—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00219	0.00667	CcSEcCtD
Tolvaptan—Decreased appetite—Teniposide—lymphatic system cancer	0.00217	0.0066	CcSEcCtD
Tolvaptan—Renal failure—Carmustine—lymphatic system cancer	0.00216	0.00658	CcSEcCtD
Tolvaptan—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00215	0.00654	CcSEcCtD
Tolvaptan—Anorexia—Fludarabine—lymphatic system cancer	0.00209	0.00636	CcSEcCtD
Tolvaptan—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00207	0.0063	CcSEcCtD
Tolvaptan—Feeling abnormal—Teniposide—lymphatic system cancer	0.00205	0.00626	CcSEcCtD
Tolvaptan—Renal failure—Mitoxantrone—lymphatic system cancer	0.00201	0.00612	CcSEcCtD
Tolvaptan—Nausea—Mechlorethamine—lymphatic system cancer	0.00201	0.00612	CcSEcCtD
Tolvaptan—Body temperature increased—Teniposide—lymphatic system cancer	0.00197	0.006	CcSEcCtD
Tolvaptan—Hyperuricaemia—Methotrexate—lymphatic system cancer	0.00196	0.00598	CcSEcCtD
Tolvaptan—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00194	0.00591	CcSEcCtD
Tolvaptan—Decreased appetite—Fludarabine—lymphatic system cancer	0.0019	0.0058	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00189	0.00576	CcSEcCtD
Tolvaptan—Constipation—Fludarabine—lymphatic system cancer	0.00187	0.00571	CcSEcCtD
Tolvaptan—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00186	0.00567	CcSEcCtD
Tolvaptan—Blood uric acid increased—Methotrexate—lymphatic system cancer	0.00185	0.00565	CcSEcCtD
Tolvaptan—Respiratory failure—Methotrexate—lymphatic system cancer	0.00185	0.00565	CcSEcCtD
Tolvaptan—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00185	0.00564	CcSEcCtD
Tolvaptan—Urethral disorder—Vincristine—lymphatic system cancer	0.00185	0.00563	CcSEcCtD
Tolvaptan—Hypersensitivity—Teniposide—lymphatic system cancer	0.00184	0.00559	CcSEcCtD
Tolvaptan—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00183	0.00556	CcSEcCtD
Tolvaptan—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00182	0.00555	CcSEcCtD
Tolvaptan—Feeling abnormal—Fludarabine—lymphatic system cancer	0.0018	0.0055	CcSEcCtD
Tolvaptan—Asthenia—Teniposide—lymphatic system cancer	0.00179	0.00545	CcSEcCtD
Tolvaptan—Malaise—Bleomycin—lymphatic system cancer	0.00177	0.00541	CcSEcCtD
Tolvaptan—Pruritus—Teniposide—lymphatic system cancer	0.00176	0.00537	CcSEcCtD
Tolvaptan—Cardiac disorder—Vincristine—lymphatic system cancer	0.00175	0.00533	CcSEcCtD
Tolvaptan—Body temperature increased—Fludarabine—lymphatic system cancer	0.00173	0.00528	CcSEcCtD
Tolvaptan—Malnutrition—Carmustine—lymphatic system cancer	0.00172	0.00523	CcSEcCtD
Tolvaptan—Angiopathy—Vincristine—lymphatic system cancer	0.00171	0.00521	CcSEcCtD
Tolvaptan—Diarrhoea—Teniposide—lymphatic system cancer	0.0017	0.0052	CcSEcCtD
Tolvaptan—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0017	0.00517	CcSEcCtD
Tolvaptan—Discomfort—Bleomycin—lymphatic system cancer	0.00165	0.00504	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—lymphatic system cancer	0.00165	0.00501	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—lymphatic system cancer	0.00165	0.00501	CcSEcCtD
Tolvaptan—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00161	0.00492	CcSEcCtD
Tolvaptan—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00161	0.00489	CcSEcCtD
Tolvaptan—Asthenia—Fludarabine—lymphatic system cancer	0.00157	0.00479	CcSEcCtD
Tolvaptan—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00156	0.00476	CcSEcCtD
Tolvaptan—Headache—Teniposide—lymphatic system cancer	0.00156	0.00476	CcSEcCtD
Tolvaptan—Pruritus—Fludarabine—lymphatic system cancer	0.00155	0.00472	CcSEcCtD
Tolvaptan—Anorexia—Bleomycin—lymphatic system cancer	0.00153	0.00466	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—lymphatic system cancer	0.0015	0.00458	CcSEcCtD
Tolvaptan—Diarrhoea—Fludarabine—lymphatic system cancer	0.0015	0.00457	CcSEcCtD
Tolvaptan—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00148	0.00451	CcSEcCtD
Tolvaptan—Nausea—Teniposide—lymphatic system cancer	0.00148	0.00451	CcSEcCtD
Tolvaptan—Malaise—Mitoxantrone—lymphatic system cancer	0.00144	0.00439	CcSEcCtD
Tolvaptan—Decreased appetite—Bleomycin—lymphatic system cancer	0.0014	0.00425	CcSEcCtD
Tolvaptan—Headache—Fludarabine—lymphatic system cancer	0.00137	0.00418	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00135	0.00411	CcSEcCtD
Tolvaptan—Discomfort—Mitoxantrone—lymphatic system cancer	0.00134	0.00409	CcSEcCtD
Tolvaptan—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00134	0.00408	CcSEcCtD
Tolvaptan—Anorexia—Carmustine—lymphatic system cancer	0.00134	0.00407	CcSEcCtD
Tolvaptan—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00132	0.00403	CcSEcCtD
Tolvaptan—Nervous system disorder—Vincristine—lymphatic system cancer	0.00131	0.004	CcSEcCtD
Tolvaptan—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0013	0.00397	CcSEcCtD
Tolvaptan—Nausea—Fludarabine—lymphatic system cancer	0.0013	0.00396	CcSEcCtD
Tolvaptan—Shock—Mitoxantrone—lymphatic system cancer	0.00128	0.00391	CcSEcCtD
Tolvaptan—Anorexia—Vincristine—lymphatic system cancer	0.00128	0.00389	CcSEcCtD
Tolvaptan—Body temperature increased—Bleomycin—lymphatic system cancer	0.00127	0.00387	CcSEcCtD
Tolvaptan—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00127	0.00386	CcSEcCtD
Tolvaptan—Anorexia—Mitoxantrone—lymphatic system cancer	0.00124	0.00378	CcSEcCtD
Tolvaptan—Decreased appetite—Carmustine—lymphatic system cancer	0.00122	0.00371	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00121	0.00369	CcSEcCtD
Tolvaptan—Constipation—Carmustine—lymphatic system cancer	0.0012	0.00365	CcSEcCtD
Tolvaptan—Breast disorder—Methotrexate—lymphatic system cancer	0.00119	0.00364	CcSEcCtD
Tolvaptan—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00118	0.0036	CcSEcCtD
Tolvaptan—Decreased appetite—Vincristine—lymphatic system cancer	0.00116	0.00354	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00116	0.00352	CcSEcCtD
Tolvaptan—Feeling abnormal—Carmustine—lymphatic system cancer	0.00115	0.00352	CcSEcCtD
Tolvaptan—Asthenia—Bleomycin—lymphatic system cancer	0.00115	0.00351	CcSEcCtD
Tolvaptan—Constipation—Vincristine—lymphatic system cancer	0.00114	0.00349	CcSEcCtD
Tolvaptan—Pruritus—Bleomycin—lymphatic system cancer	0.00114	0.00346	CcSEcCtD
Tolvaptan—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00113	0.00345	CcSEcCtD
Tolvaptan—Constipation—Mitoxantrone—lymphatic system cancer	0.00111	0.0034	CcSEcCtD
Tolvaptan—Body temperature increased—Carmustine—lymphatic system cancer	0.00111	0.00338	CcSEcCtD
Tolvaptan—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00107	0.00327	CcSEcCtD
Tolvaptan—Body temperature increased—Vincristine—lymphatic system cancer	0.00106	0.00322	CcSEcCtD
Tolvaptan—Hypersensitivity—Carmustine—lymphatic system cancer	0.00103	0.00315	CcSEcCtD
Tolvaptan—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00103	0.00314	CcSEcCtD
Tolvaptan—Asthenia—Carmustine—lymphatic system cancer	0.00101	0.00306	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—lymphatic system cancer	0.001	0.00305	CcSEcCtD
Tolvaptan—Hypersensitivity—Vincristine—lymphatic system cancer	0.000986	0.003	CcSEcCtD
Tolvaptan—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00096	0.00293	CcSEcCtD
Tolvaptan—Asthenia—Vincristine—lymphatic system cancer	0.00096	0.00293	CcSEcCtD
Tolvaptan—Diarrhoea—Carmustine—lymphatic system cancer	0.000959	0.00292	CcSEcCtD
Tolvaptan—Nausea—Bleomycin—lymphatic system cancer	0.000954	0.00291	CcSEcCtD
Tolvaptan—Asthenia—Mitoxantrone—lymphatic system cancer	0.000935	0.00285	CcSEcCtD
Tolvaptan—Dizziness—Carmustine—lymphatic system cancer	0.000927	0.00282	CcSEcCtD
Tolvaptan—Diarrhoea—Vincristine—lymphatic system cancer	0.000915	0.00279	CcSEcCtD
Tolvaptan—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000902	0.00275	CcSEcCtD
Tolvaptan—Urethral disorder—Methotrexate—lymphatic system cancer	0.000896	0.00273	CcSEcCtD
Tolvaptan—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000891	0.00272	CcSEcCtD
Tolvaptan—Dizziness—Vincristine—lymphatic system cancer	0.000885	0.0027	CcSEcCtD
Tolvaptan—Headache—Carmustine—lymphatic system cancer	0.000878	0.00268	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000848	0.00258	CcSEcCtD
Tolvaptan—Headache—Vincristine—lymphatic system cancer	0.000838	0.00255	CcSEcCtD
Tolvaptan—Nausea—Carmustine—lymphatic system cancer	0.000832	0.00254	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—lymphatic system cancer	0.000829	0.00253	CcSEcCtD
Tolvaptan—Immune system disorder—Methotrexate—lymphatic system cancer	0.000825	0.00252	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000823	0.00251	CcSEcCtD
Tolvaptan—Headache—Mitoxantrone—lymphatic system cancer	0.000816	0.00249	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—lymphatic system cancer	0.000795	0.00242	CcSEcCtD
Tolvaptan—Nausea—Vincristine—lymphatic system cancer	0.000795	0.00242	CcSEcCtD
Tolvaptan—Dysgeusia—Methotrexate—lymphatic system cancer	0.000779	0.00237	CcSEcCtD
Tolvaptan—Nausea—Mitoxantrone—lymphatic system cancer	0.000774	0.00236	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000738	0.00225	CcSEcCtD
Tolvaptan—Malaise—Methotrexate—lymphatic system cancer	0.000717	0.00219	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000673	0.00205	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—lymphatic system cancer	0.000669	0.00204	CcSEcCtD
Tolvaptan—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000649	0.00198	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000637	0.00194	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—lymphatic system cancer	0.000631	0.00192	CcSEcCtD
Tolvaptan—Anorexia—Methotrexate—lymphatic system cancer	0.000619	0.00189	CcSEcCtD
Tolvaptan—Decreased appetite—Methotrexate—lymphatic system cancer	0.000564	0.00172	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.00056	0.00171	CcSEcCtD
Tolvaptan—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000535	0.00163	CcSEcCtD
Tolvaptan—Body temperature increased—Methotrexate—lymphatic system cancer	0.000513	0.00156	CcSEcCtD
Tolvaptan—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000478	0.00146	CcSEcCtD
Tolvaptan—Asthenia—Methotrexate—lymphatic system cancer	0.000466	0.00142	CcSEcCtD
Tolvaptan—Pruritus—Methotrexate—lymphatic system cancer	0.000459	0.0014	CcSEcCtD
Tolvaptan—Diarrhoea—Methotrexate—lymphatic system cancer	0.000444	0.00135	CcSEcCtD
Tolvaptan—Dizziness—Methotrexate—lymphatic system cancer	0.000429	0.00131	CcSEcCtD
Tolvaptan—Headache—Methotrexate—lymphatic system cancer	0.000407	0.00124	CcSEcCtD
Tolvaptan—Nausea—Methotrexate—lymphatic system cancer	0.000386	0.00118	CcSEcCtD
